nach oben

Wiener klinische Wochenschrift Education

Erschienen in:

01.12.2015

Therapie der Hepatitis C Virusinfektion

verfasst von: Clarissa Freissmuth, Peter Ferenci, Ao. Univ. Prof. Dr. Harald Hofer

Erschienen in: Wiener klinische Wochenschrift Education | Ausgabe 3-4/2015

Einloggen, um Zugang zu erhalten

Auszug

Die Therapie der chronischen Hepatitis C hat in den letzten Jahren große Weiterentwicklungen erfahren. Mittels antiviraler Therapie kann die chronische Virusinfektion mittlerweile in der überwiegenden Mehrzahl der Patienten dauerhaft ausgeheilt werden. Langjährige Säulen der antiviralen Therapie wie Interferon, Steuerung der Therapiedauer nach initialem Ansprechen („response guided therapy“), Bestimmung des IL-28B Genotyps oder die Durchführung einer Leberbiopsie sind mit der Verfügbarkeit von neuen direkt antiviral wirksamen Substanzen zunehmend in den Hintergrund geraten. Mit der Zulassung der direkt antiviralen Substanzen kam es auch zu einer deutlichen Erweiterung des Spektrums der Behandlung von Patienten mit chronischer Hepatitis C, da auch Patienten mit fortgeschrittener Lebererkrankung oder Kontraindikationen gegen Interferon überaus wirkungsvoll und sicher therapiert werden können.

Die Therapie der chronischen Hepatitis C hat in den letzten Jahren große Fortschritte gemacht

…

Nächster Artikel Pulmonale Hypertension

Nur mit Berechtigung zugänglich

Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.CrossRefPubMed

Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–33.CrossRefPubMed

Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–91.CrossRefPubMed

Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–4.CrossRefPubMed

Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: a high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.CrossRefPubMed

Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C-virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.CrossRefPubMed

Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999;354:2119–24.CrossRefPubMed

Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.PubMedCentralCrossRefPubMed

Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78–85.CrossRefPubMed

10.

Beinhardt S, Payer BA, Datz C, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59:972–7.CrossRefPubMed

11.

Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20 year multicenter study. Hepatology. 2000;32:91–6.CrossRefPubMed

12.

Nomura H, Tanimoto H, Nagahama T, et al. Short-term interferon-alfa therapy for acute hepatitis C. Hepatology. 2004;39:1213–9.CrossRefPubMed

13.

Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2014. pii: gutjnl-2014-306997. doi:10.1136/gutjnl-2014-306997.

14.

Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344–50.CrossRefPubMed

15.

Licata A, DiBona D, Schepis F, et al. When and how to treat acute hepatitis C. J Hepatol. 2003;39:1056–62.CrossRefPubMed

16.

Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.CrossRefPubMed

17.

Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:521–31.CrossRefPubMed

18.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. doi:10.1001/jama.2012.144878.CrossRefPubMed

19.

Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QEST-1, a phase III trial. Lancet. 2014;384:403–13.CrossRefPubMed

20.

Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet. 2014;384:414–26.CrossRefPubMed

21.

Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic Hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed

22.

Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65. doi:10.1016/S0140–6736(14)61036–9. (Epub 2014 Jul 28).CrossRefPubMed

23.

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefPubMed

24.

Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMed

25.

Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMed

26.

Bourliere M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014;60(Suppl 1):239A.

27.

Bourliere M, et al. Sofosbuvir/Ledipasvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed to protease inhibitor based triple therapy. Hepatology. 2014;60:1270A.

28.

Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed

29.

Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65.CrossRefPubMed

30.

Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed

31.

Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefPubMed

32.

Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed

33.

Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMed

34.

Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMed

35.

Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015. doi:10.1002/hep.27726.

36.

Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014;60:1275A.

37.

Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129–30A.

38.

Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014;60(Suppl 1):321A.

39.

Beinhardt S, Peck-Radosavjevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of liver transplant patients with chronic hepatitis C. Transpl Int. 2015. doi:10.1111/tri.12577.

Titel: Therapie der Hepatitis C Virusinfektion
verfasst von: Clarissa Freissmuth
Peter Ferenci
Ao. Univ. Prof. Dr. Harald Hofer
Publikationsdatum: 01.12.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift Education / Ausgabe 3-4/2015
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765
DOI: https://doi.org/10.1007/s11812-015-0072-7

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten